Refine
Has Fulltext
- yes (23)
Is part of the Bibliography
- yes (23)
Year of publication
Document Type
- Journal article (23) (remove)
Language
- English (23)
Keywords
- ADHD (5)
- mice (3)
- prefrontal cortex (3)
- serotonin (3)
- SLC2A3 (2)
- attention-deficit/hyperactivity disorder (ADHD) (2)
- chronic stress (2)
- hippocampus (2)
- neurodevelopment (2)
- pro-inflammatory cytokines (2)
- psychiatric disorders (2)
- 3-dimensional MRI (1)
- 5-HT receptors (1)
- 5-HTT (1)
- 5-HTTLPR polymorphism (1)
- Adult (1)
- Aggression (1)
- Antisocial behavior (1)
- Association (1)
- C57BL/6 mice (1)
- CB1 receptor antagonists (1)
- COMT (1)
- Central nervous system (1)
- Conduct disorder (1)
- DRD4 (1)
- Deficit/hyperactivity disorder (1)
- Diagnostic approach (1)
- Dopamine (1)
- Fgf-signalling (1)
- GLUT3 (1)
- GWAS (1)
- Gene (1)
- Hypothalamus (1)
- Large multicenter ADHD (1)
- NMDA receptor subunits NR2A and NR2B (1)
- OXTR (1)
- Rating scale (1)
- SARS-CoV-2 (1)
- SSRI (1)
- Serotonin (1)
- Susceptibility loci (1)
- T-cadherin (1)
- Xenopus laevis oocytes (1)
- adulthood (1)
- aging (1)
- allostatic load (1)
- amino acid analysis (1)
- anhedonia (1)
- animal behavior (1)
- animal behaviour (1)
- antioxidant nutrients (1)
- anxiety (1)
- anxiety-like behavior (1)
- association (1)
- attention (1)
- blood flow (1)
- cadherin-13 (CDH13) (1)
- celecoxib (1)
- cell membranes (1)
- childhood maltreatment (1)
- chronic social stress (1)
- citalopram (1)
- collagens (1)
- comparative genomics (1)
- copy number variation (1)
- crystal structure (1)
- dangerous world (1)
- depression (1)
- developmental plasticity (1)
- dicholine succinate (1)
- dorsal raphe (1)
- electroencephalogram (EEG) (1)
- elevated plus-maze (1)
- energy metabolism (1)
- environment interaction (1)
- environmental enrichment (1)
- events (1)
- false belief (1)
- fear conditioning (1)
- female aggression (1)
- forced swimming (1)
- genetic variants (1)
- genetics of the nervous system (1)
- glucose (1)
- glucose transporter (1)
- glycogen synthase kinase-3 β (GSK-3β) (1)
- hippocampal neurogenesis (1)
- hippocampal plasticity (1)
- hyperactivity (1)
- impulsivity (1)
- induced pluripotent stem cells (1)
- inducible cyclooxygenase-2 (COX-2) (1)
- inflammation (1)
- insulin receptor (1)
- insulin receptor (IR) (1)
- integrins (1)
- ischemic stroke (1)
- knockout mice (1)
- lactosylceramide alpha-2,3-sialyltransferase (ST3GAL5) (1)
- lerned helplessness (1)
- life history (1)
- life stress (1)
- linked polymorphic region (1)
- major depression (1)
- match-mismatch (1)
- maternal care (1)
- membrane potential (1)
- membrane proteins (1)
- metaanalysis (1)
- moderation (1)
- molecular neuroscience (1)
- mouse (1)
- mouse model (1)
- mouse-brain (1)
- myelination (1)
- neurodegeneration (1)
- oxidative stress (1)
- phosphorylated glycogen synthase kinase-3beta (pGSK-3beta) (1)
- platelet activation (1)
- platelet aggregation (1)
- platelets (1)
- polygenic risk score (1)
- polymorphism (1)
- post-traumatic stress disorder (1)
- predation stress (1)
- predictive adaptive response hypothesis (1)
- radial glia (1)
- rare mendelian disorders (1)
- rhesus macaques (1)
- s allele (1)
- serotonin transporter gene (1)
- sex differences (1)
- sialic acid (1)
- sialyltransferase (1)
- sleep EEG (1)
- social behaviour (1)
- stress resilience (1)
- substance abuse disorder (1)
- theory of mind (1)
- toll-like receptors (1)
- tryptophan hydroxylase-2 (Tph2) (1)
- venturesomeness (1)
- white-matter integrity (1)
Institute
- Lehrstuhl für Molekulare Psychiatrie (23) (remove)
Recent advances in the genetics of neurodevelopmental disorders (NDDs) have identified the transcription factor FOXP2 as one of numerous risk genes, e.g. in autism spectrum disorders (ASD) and attention-deficit/hyperactivity disorder (ADHD). FOXP2 function is suggested to be involved in GABAergic signalling and numerous studies demonstrate that GABAergic function is altered in NDDs, thus disrupting the excitation/inhibition balance. Interestingly, GABAergic signalling components, including glutamate-decarboxylase 1 (Gad1) and GABA receptors, are putative transcriptional targets of FOXP2. However, the specific role of FOXP2 in the pathomechanism of NDDs remains elusive. Here we test the hypothesis that Foxp2 affects behavioural dimensions via GABAergic signalling using zebrafish as model organism. We demonstrate that foxp2 is expressed by a subset of GABAergic neurons located in brain regions involved in motor functions, including the subpallium, posterior tuberculum, thalamus and medulla oblongata. Using CRISPR/Cas9 gene-editing we generated a novel foxp2 zebrafish loss-of-function mutant that exhibits increased locomotor activity. Further, genetic and/or pharmacological disruption of Gad1 or GABA-A receptors causes increased locomotor activity, resembling the phenotype of foxp2 mutants. Application of muscimol, a GABA-A receptor agonist, rescues the hyperactive phenotype induced by the foxp2 loss-of-function. By reverse translation of the therapeutic effect on hyperactive behaviour exerted by methylphenidate, we note that application of methylphenidate evokes different responses in wildtype compared to foxp2 or gad1b loss-of-function animals. Together, our findings support the hypothesis that foxp2 regulates locomotor activity via GABAergic signalling. This provides one targetable mechanism, which may contribute to behavioural phenotypes commonly observed in NDDs.
Background
While all efforts have been undertaken to propagate the vaccination and develop remedies against SARS-CoV-2, no satisfactory management of this infection is available yet. Moreover, poor availability of any preventive and treatment measures of SARS-CoV-2 in economically disadvantageous communities aggravates the course of the pandemic. Here, we studied a new immunomodulatory phytotherapy (IP), an extract of blackberry, chamomile, garlic, cloves, and elderberry as a potential low-cost solution for these problems given the reported efficacy of herbal medicine during the previous SARS virus outbreak.
Methods
The key feature of SARS-CoV-2 infection, excessive inflammation, was studied in in vitro and in vivo assays under the application of the IP. First, changes in tumor-necrosis factor (TNF) and lnteurleukin-1 beta (IL-1β) concentrations were measured in a culture of human macrophages following the lipopolysaccharide (LPS) challenge and treatment with IP or prednisolone. Second, chronically IP-pre-treated CD-1 mice received an agonist of Toll-like receptors (TLR)-7/8 resiquimod and were examined for lung and spleen expression of pro-inflammatory cytokines and blood formula. Finally, chronically IP-pre-treated mice challenged with LPS injection were studied for “sickness” behavior. Additionally, the IP was analyzed using high-potency-liquid chromatography (HPLC)-high-resolution-mass-spectrometry (HRMS).
Results
LPS-induced in vitro release of TNF and IL-1β was reduced by both treatments. The IP-treated mice displayed blunted over-expression of SAA-2, ACE-2, CXCL1, and CXCL10 and decreased changes in blood formula in response to an injection with resiquimod. The IP-treated mice injected with LPS showed normalized locomotion, anxiety, and exploration behaviors but not abnormal forced swimming. Isoquercitrin, choline, leucine, chlorogenic acid, and other constituents were identified by HPLC-HRMS and likely underlie the IP immunomodulatory effects.
Conclusions
Herbal IP-therapy decreases inflammation and, partly, “sickness behavior,” suggesting its potency to combat SARS-CoV-2 infection first of all via its preventive effects.
The neurotransmitter serotonin plays a key role in the control of aggressive behaviour. While so far most studies have investigated variation in serotonin levels, a recently created tryptophan hydroxylase 2 (Tph2) knockout mouse model allows studying effects of complete brain serotonin deficiency. First studies revealed increased aggressiveness in homozygous Tph2 knockout mice in the context of a resident-intruder paradigm. Focussing on females, this study aimed to elucidate effects of serotonin deficiency on aggressive and non-aggressive social behaviours not in a test situation but a natural setting. For this purpose, female Tph2 wildtype (n = 40) and homozygous knockout mice (n = 40) were housed with a same-sex conspecific of either the same or the other genotype in large terraria. The main findings were: knockout females displayed untypically high levels of aggressive behaviour even after several days of co-housing. Notably, in response to aggressive knockout partners, they showed increased levels of defensive behaviours. While most studies on aggression in rodents have focussed on males, this study suggests a significant involvement of serotonin also in the control of female aggression. Future research will show, whether the observed behavioural effects are directly caused by the lack of serotonin or by potential compensatory mechanisms.